In the last two decades, there has been a shift in the paradigm of RA treatment and there is consensus for earlier interventions to control inflammation, retard the progression of structural damage and preserve function and quality of life. Thus, the final objective is to obtain the remission of disease. However, the optimal therapeutic strategy remains unknown.
The advantage of treating RA early with DMARD therapy compared to its delayed institution is clear. Moreover, combination therapy including moderate to high doses of glucocorticoids and combinations of methotrexate with tumour necrosis factor blockers are more effective than monotherapies.
We review here the different treatments strategies studied in early RA.